{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:43:49Z","timestamp":1785282229068,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T01:34:54Z","timestamp":1662600894000},"page":"6042-6047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X\u00a0in a seroprevalence study in Niger, West Africa"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0196-0383","authenticated-orcid":false,"given":"Sara","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Townsend-Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Louth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lee-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Dan Dano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.08.013_b0005","doi-asserted-by":"crossref","unstructured":"Peterson ME, Li Y, Bita A, Moureau A, Nair H, Kyaw MH, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9:010409.","DOI":"10.7189\/jogh.09.010409"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.013_b0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jinf.2019.10.018","article-title":"Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe","volume":"79","author":"Bai","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2022.08.013_b0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/cid\/ciy489","article-title":"Sustaining Protection Against Epidemic Meningitis in Africa After Vaccination","volume":"68","author":"Greenwood","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2022.08.013_b0020","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.013_b0025","author":"WHO. Meningitis Weekly Bulletin. World Health","year":"2018","journal-title":"Organization"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.013_b0030","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Burns","year":"2001","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.013_b0035","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","article-title":"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study","volume":"18","author":"Chen","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2022.08.013_b0040","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMoa2013615","article-title":"Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers","volume":"384","author":"Tapia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.013_b0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-9202-7_12","article-title":"Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays","volume":"1969","author":"Lucidarme","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2022.08.013_b0050","article-title":"Bioanalytical Method Validation -","author":"Fda","year":"2018","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.vaccine.2022.08.013_b0055","doi-asserted-by":"crossref","unstructured":"Peterson ME, Li Y, Shanks H, Mile R, Nair H, Kyaw MH, et al. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. BMJ Open. 2019;9:e024343.","DOI":"10.1136\/bmjopen-2018-024343"},{"issue":"12","key":"10.1016\/j.vaccine.2022.08.013_b0060","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(07)70288-8","article-title":"Meningococcal carriage in the African meningitis belt","volume":"7","author":"Trotter","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.013_b0065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.08.013_b0070","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1360-2276.2003.01126.x","article-title":"Outbreaks of serogroup X meningococcal meningitis in Niger 1995\u20132000","volume":"8","author":"Djibo","year":"2003","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2022.08.013_b0075","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2022.08.013_b0080","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1128\/IAI.71.12.6712-6720.2003","article-title":"Genetic basis for biosynthesis of the (alpha 1\u2013>4)-linked N-acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X","volume":"71","author":"Tzeng","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2022.08.013_b0085","doi-asserted-by":"crossref","unstructured":"Muindi KM, McCarthy PC, Wang T, Vionnet J, Battistel M, Jankowska E, et al. Characterization of the meningococcal serogroup X capsule N-acetylglucosamine-1-phosphotransferase. Glycobiology. 2014;24:139-49.","DOI":"10.1093\/glycob\/cwt091"},{"key":"10.1016\/j.vaccine.2022.08.013_b0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.carres.2018.06.007","article-title":"Conformations of Neisseria meningitidis serogroup A and X polysaccharides: The effects of chain length and O-acetylation","volume":"465","author":"Hlozek","year":"2018","journal-title":"Carbohydr Res"},{"issue":"11-12","key":"10.1016\/j.vaccine.2022.08.013_b0095","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0264-410X(02)00630-8","article-title":"Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era","volume":"21","author":"Trotter","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.013_b0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"45","key":"10.1016\/j.vaccine.2022.08.013_b0105","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.vaccine.2018.05.081","article-title":"The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci","volume":"36","author":"Harris","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.013_b0110","doi-asserted-by":"crossref","unstructured":"Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737-43.","DOI":"10.1086\/527401"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200977X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200977X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:15Z","timestamp":1759403955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2200977X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":22,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X2200977X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X\u00a0in a seroprevalence study in Niger, West Africa","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}